Rationale and design of the carotid plaque in human for all evaluations with aggressive rosuvastatin therapy (CHALLENGER Trial) - Evaluation by magnetic resonance imaging

Circulation Journal

Volumn 73, Issue 1, 2009, Pages 111-115

  Miyauchi, Katsumi ^a   Takaya, Norihide ^a   Hirose, Takahisa ^a   Ikeda, Fuki ^a   Kawamori, Ryuzo ^a   Ohishi, Hidenori ^a   Yoshida, Kensaku ^a   Yamamoto, Munetaka ^a   Arai, Hajime ^a   Urabe, Takao ^a   Hattori, Nobutaka ^a   Suzuki, Michimasa ^a   Maehara, Tadayuki ^a   Sase, Kazuhiro ^a   Hatsukami, Thomas S ^b,c   Yuan, Chun ^b   Daida, Hiroyuki ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Carotid intima media thickness; Carotid plaque; High resolution magnetic resonance imaging; Plaque stability; Rosuvastatin

Indexed keywords

ROSUVASTATIN;

ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY; CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANGIOGRAPHY; CAROTID STENOSIS; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDPOINT DETERMINATION; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; JAPAN; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; PYRIMIDINES; SULFONAMIDES; TUNICA INTIMA; TUNICA MEDIA;

EID: 58549096502     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-0135     Document Type: Article

References (27)

1. Kiyohara Y. Epidemiology of myocardial and cerebral infarction. Cardioangiology 2006; 59: 417-423.
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
3. Chau J, Cheung BM, McGhee SM, Lauder IJ, Lau CP, Kumana CR. Cost-effectiveness analysis of applying the Cholesterol and Recurrent Events (CARE) study protocol in Hong Kong. Hong Kong Med J 2001; 7: 360-368.
4. Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: Results from the LIPID trial. Diabetes Care 2003; 26: 2713-2721.
5. Matsumoto M. Carotid atherosclerosis and lipid-lowering treatment: Assessment with ultrasonography. Cardioangiology 2005; 57: 42-49.
6. Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: Systematic review and up-to-date meta-analysis. Stroke 2004; 35: 2902-2909.
7. Takayama T, Hiro T, Yamagishi M, Daida H, Saito S, Yamaguchi T, et al. Rationale and design for a study using intravascular ultrasound to evaluate effects of rosuvastatin on coronary artery atheroma in Japanese subjects: COSMOS study (Coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese patients. Circ J 2007; 71: 271-275.
8. Miyauchi K, Kiumura T, Morimoto T, Nakagawa Y, Yamagishi M, Ozaki Y, et al. Japan Assessment of pitavastatin and atprvastatin in acute coronay syndrome (JAPAN-ACS): Rationale and Design. Circ J 2006; 70: 1624-1628.
9. Birgelen C, Hartmann M, Mintz GS, Baumgart D, Schmermund A, Erbel R. Relation between progression and regression of atherosclerotic left main coronary artery disease and serum cholesterol levels as assessed with serial long-term (12 months) follow-up intravascular ultrasound. Circulation 2003; 108: 2757-2762.
10. Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, et al. Early statin treatment in patients with acute coronary syndrome: Demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary events: The ESTABLISH study. Circulation 2004; 110: 1061-1068.
11. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTERID trial. JAMA 2006; 295: 1556-1565.
12. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation 2001; 103: 926-933.
13. Chu B, Hatsukami TS, Polissar NL, Zhao XQ, Kraiss LW, Parker DL, et al. Determination of carotid artery atherosclerotic lesion type and distribution in hypercholesterolemic patients with moderate carotid stenosis using noninvasive magnetic resonance imaging. Stroke 2004; 35: 2444-2448.
14. Underhill HR, Hatsukami TS, Raichlen JS, Waterton J, Liu F, Kerwin WS, et al. Morphology-enhanced probabilistic plaque segmentation identifies regression of the lipid-rich portion of carotid plaques after 2 years of rosuvastatin therapy. Circulation 2006; 114: 377-378.
15. Underhill HR, Yuan C, Zhao XQ, Kraiss LW, Parker DL, Saam T, et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: A high-resolution magnetic resonance imaging trial. Am Heart J 2007; 155: 584e1-584e8.
16. Watanabe K, Sugiyama S, Kugiyama K, Honda O, Fukushima H, Koga H, et al. Atherosclerosis evaluation by ultrasound: Stabilization of carotid atheroma assessed by quantitative ultrasound analysis in nonhypercholesterolemic patients with coronary artery disease. J Am Coll Cardiol 2005; 46: 2022-2030.
17. Takaya N, Cai J, Ferguson MS, Yarnykh VL, Chu B, Saam T, et al. Intra- and interreader reproducibility of magnetic resonance imaging for quantifying the lipid-rich necrotic core is improved with gadolinium contrast enhancement. J Magn Reson Imaging 2006; 24: 203-210.
18. Saam T, Hatsukami TS, Yarnykh VL, Hayes CE, Underhill H, Chu B, et al. Reader and platform reproducibility for quantitative assessment of carotid atherosclerotic plaque using 1.5T Siemens, Philips, and General Electric scanners. J Magn Reson Imaging 2007; 26: 344-352.
19. Kerwin WS, Han C, Chu B. A quantitative vascular analysis system for evaluation of atherosclerotic lesions by MRI. In: Proceedings of the 4th International Conference on Medical Image Computing and Computer-Assisted Intervention (MICCAI), Utrecht, The Netherlands, 14-17 October 2001. Lecture Notes in Computing Science 2208 edn. Berlin: Springer; 2001; 786-794.
20. Liu F, Xu D, Ferguson MS, Chu B, Saam T, Takaya N, et al. Automated in vivo segmentation of carotid plaque MRI with Morphology-Enhanced probability maps Magn Reson Med 2006; 55: 659-668.
21. National Cholesterol Education Program (NECP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NECP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adult treatment panel III) final report. Circulation 2002; 106: 3143-3421.
22. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, et al. Executive Summary of Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases for Japanese. J Atheroscler Thromb 2007; 14: 45-50.
23. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
24. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-1622.
25. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 34: 498-511.
26. Schuster H. The GALAXY program: An update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Rev Cardiovasc Ther 2007; 5: 177-192.
27. Crouse JR III, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis. JAMA 2007; 297: 1344-1353.